Summary
Global Markets Direct’s, ‘Liver Cirrhosis - Pipeline Review, H1 2016’, provides an overview of the Liver Cirrhosis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Liver Cirrhosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Liver Cirrhosis
- The report reviews pipeline therapeutics for Liver Cirrhosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Liver Cirrhosis therapeutics and enlists all their major and minor projects
- The report assesses Liver Cirrhosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Liver Cirrhosis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Liver Cirrhosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Liver Cirrhosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Conatus Pharmaceuticals Inc.
Digna Biotech, S.L.
Galectin Therapeutics, Inc.
Gilead Sciences, Inc.
GNI Group Ltd.
Human Stem Cells Institute
INVENT Pharmaceuticals, Inc.
Nimbus Therapeutics, LLC
Pacific Therapeutics Ltd.
PharmaIN Corporation
Pharmicell Co., Ltd.
S-Evans Biosciences, Inc.
Stelic Institute & Co., Inc.
Stempeutics Research Private Limited
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Liver Cirrhosis Overview 9
Therapeutics Development 10
Pipeline Products for Liver Cirrhosis - Overview 10
Pipeline Products for Liver Cirrhosis - Comparative Analysis 11
Liver Cirrhosis - Therapeutics under Development by Companies 12
Liver Cirrhosis - Therapeutics under Investigation by Universities/Institutes 13
Liver Cirrhosis - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Liver Cirrhosis - Products under Development by Companies 17
Liver Cirrhosis - Products under Investigation by Universities/Institutes 18
Liver Cirrhosis - Companies Involved in Therapeutics Development 19
Conatus Pharmaceuticals Inc. 19
Digna Biotech, S.L. 20
Galectin Therapeutics, Inc. 21
Gilead Sciences, Inc. 22
GNI Group Ltd. 23
Human Stem Cells Institute 24
INVENT Pharmaceuticals, Inc. 25
Nimbus Therapeutics, LLC 26
Pacific Therapeutics Ltd. 27
PharmaIN Corporation 28
Pharmicell Co., Ltd. 29
S-Evans Biosciences, Inc. 30
Stelic Institute & Co., Inc. 31
Stempeutics Research Private Limited 32
Liver Cirrhosis - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Combination Products 34
Assessment by Target 35
Assessment by Mechanism of Action 37
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
(sofosbuvir + velpatasvir) - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
DB-027 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
DB-036 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
emricasan - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
F-351 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Gemacell - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
GRMD-02 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
GXHPC-1 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
INV-340 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Livercellgram - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Monoclonal Antibodies to Antagonize TGF-Beta Receptor Type-1 for HCV associated Liver Cirrhosis - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ND-654 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
PTL-303 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Stem Cell Therapy for Liver Cirrhosis - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Stem Cell Therapy for Metabolic, Gastrointestinal and Respiratory Disorders - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Stem Cell Therapy for Rheumatoid Arthritis and Liver Cirrhosis - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Stempeucel - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
STNM-04 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Synthetic Peptide for Liver Cirrhosis - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
thrombopoietin - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Liver Cirrhosis - Recent Pipeline Updates 73
Liver Cirrhosis - Dormant Projects 90
Liver Cirrhosis - Discontinued Products 91
Liver Cirrhosis - Product Development Milestones 92
Featured News & Press Releases 92
Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial 92
Nov 16, 2015: Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting 93
Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting 94
Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting 94
Oct 01, 2015: Conatus Pharmaceuticals Announces Acceptance of Abstracts for AASLD Annual Meeting 95
Jun 25, 2015: Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan Confirming Activity of Relevant Mechanisms and Opportunity for Histological Improvement 95
May 14, 2015: Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam 97
Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting 98
Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting 99
Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension 99
Appendix 101
Methodology 101
Coverage 101
Secondary Research 101
Primary Research 101
Expert Panel Validation 101
Contact Us 101
Disclaimer 102
List of Tables
Number of Products under Development for Liver Cirrhosis, H1 2016 10
Number of Products under Development for Liver Cirrhosis - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Development, H1 2016 16
Products under Development by Companies, H1 2016 17
Products under Investigation by Universities/Institutes, H1 2016 18
Liver Cirrhosis - Pipeline by Conatus Pharmaceuticals Inc., H1 2016 19
Liver Cirrhosis - Pipeline by Digna Biotech, S.L., H1 2016 20
Liver Cirrhosis - Pipeline by Galectin Therapeutics, Inc., H1 2016 21
Liver Cirrhosis - Pipeline by Gilead Sciences, Inc., H1 2016 22
Liver Cirrhosis - Pipeline by GNI Group Ltd., H1 2016 23
Liver Cirrhosis - Pipeline by Human Stem Cells Institute, H1 2016 24
Liver Cirrhosis - Pipeline by INVENT Pharmaceuticals, Inc., H1 2016 25
Liver Cirrhosis - Pipeline by Nimbus Therapeutics, LLC, H1 2016 26
Liver Cirrhosis - Pipeline by Pacific Therapeutics Ltd., H1 2016 27
Liver Cirrhosis - Pipeline by PharmaIN Corporation, H1 2016 28
Liver Cirrhosis - Pipeline by Pharmicell Co., Ltd., H1 2016 29
Liver Cirrhosis - Pipeline by S-Evans Biosciences, Inc., H1 2016 30
Liver Cirrhosis - Pipeline by Stelic Institute & Co., Inc., H1 2016 31
Liver Cirrhosis - Pipeline by Stempeutics Research Private Limited, H1 2016 32
Assessment by Monotherapy Products, H1 2016 33
Assessment by Combination Products, H1 2016 34
Number of Products by Stage and Target, H1 2016 36
Number of Products by Stage and Mechanism of Action, H1 2016 38
Number of Products by Stage and Route of Administration, H1 2016 40
Number of Products by Stage and Molecule Type, H1 2016 42
Liver Cirrhosis Therapeutics - Recent Pipeline Updates, H1 2016 73
Liver Cirrhosis - Dormant Projects, H1 2016 90
Liver Cirrhosis - Discontinued Products, H1 2016 91
List of Figures
Number of Products under Development for Liver Cirrhosis, H1 2016 10
Number of Products under Development for Liver Cirrhosis - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Products, H1 2016 16
Assessment by Monotherapy Products, H1 2016 33
Number of Products by Top 10 Targets, H1 2016 35
Number of Products by Stage and Top 10 Targets, H1 2016 35
Number of Products by Top 10 Mechanism of Actions, H1 2016 37
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 37
Number of Products by Routes of Administration, H1 2016 39
Number of Products by Stage and Routes of Administration, H1 2016 39
Number of Products by Molecule Types, H1 2016 41
Number of Products by Stage and Molecule Types, H1 2016 41
